Rice Hall James & Associates LLC Has $2.64 Million Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Rice Hall James & Associates LLC lessened its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 3.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 76,750 shares of the company’s stock after selling 2,521 shares during the quarter. Rice Hall James & Associates LLC’s holdings in Harmony Biosciences were worth $2,641,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the company. Principal Financial Group Inc. grew its holdings in shares of Harmony Biosciences by 28.4% during the 4th quarter. Principal Financial Group Inc. now owns 208,663 shares of the company’s stock worth $7,180,000 after purchasing an additional 46,194 shares in the last quarter. Rhumbline Advisers boosted its stake in Harmony Biosciences by 18.0% in the 4th quarter. Rhumbline Advisers now owns 108,588 shares of the company’s stock valued at $3,736,000 after buying an additional 16,537 shares in the last quarter. New York State Teachers Retirement System boosted its stake in Harmony Biosciences by 2.6% in the 4th quarter. New York State Teachers Retirement System now owns 31,693 shares of the company’s stock valued at $1,091,000 after buying an additional 809 shares in the last quarter. Legato Capital Management LLC boosted its stake in Harmony Biosciences by 26.0% in the 4th quarter. Legato Capital Management LLC now owns 26,720 shares of the company’s stock valued at $919,000 after buying an additional 5,506 shares in the last quarter. Finally, Louisiana State Employees Retirement System boosted its stake in Harmony Biosciences by 26.7% in the 4th quarter. Louisiana State Employees Retirement System now owns 18,500 shares of the company’s stock valued at $637,000 after buying an additional 3,900 shares in the last quarter. Institutional investors and hedge funds own 86.23% of the company’s stock.

Insider Transactions at Harmony Biosciences

In other news, CEO Jeffrey M. Dayno sold 19,293 shares of the business’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $40.13, for a total transaction of $774,228.09. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Sandip Kapadia sold 1,775 shares of the business’s stock in a transaction on Monday, January 27th. The stock was sold at an average price of $38.05, for a total value of $67,538.75. The disclosure for this sale can be found here. Insiders sold a total of 72,452 shares of company stock worth $2,831,679 over the last 90 days. 30.80% of the stock is owned by insiders.

Harmony Biosciences Trading Up 0.3 %

HRMY stock opened at $39.09 on Wednesday. The company has a market cap of $2.23 billion, a P/E ratio of 18.53, a PEG ratio of 0.51 and a beta of 0.80. Harmony Biosciences Holdings, Inc. has a twelve month low of $28.14 and a twelve month high of $41.61. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28. The business has a fifty day moving average of $36.28 and a 200-day moving average of $35.71.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Deutsche Bank Aktiengesellschaft assumed coverage on Harmony Biosciences in a research note on Tuesday, February 11th. They issued a “buy” rating and a $55.00 price target on the stock. Cantor Fitzgerald boosted their price target on Harmony Biosciences from $51.00 to $58.00 and gave the company an “overweight” rating in a research note on Wednesday, October 30th. Needham & Company LLC reaffirmed a “buy” rating and issued a $52.00 price target on shares of Harmony Biosciences in a research note on Monday, January 13th. HC Wainwright reaffirmed a “buy” rating and issued a $75.00 price target on shares of Harmony Biosciences in a research note on Monday, January 27th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $59.00 price objective (up previously from $56.00) on shares of Harmony Biosciences in a research report on Wednesday, October 30th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $55.00.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.